• Amylin Pharmaceuticals Inc., of San Diego, reported 2011 non-GAAP operating income of $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010. Total revenues for the 12 months ending Dec. 31, 2011, were $650.7 million. Net product sales of $621 .6 million included $517.7 million for Byetta (exenatide) and $103.9 million for Symlin (pramlintide acetate). In comparison, Amylin reported net product sales of $651.1 million in 2010, including $559.3 million for Byetta and $91.8 million for Symlin. Non-GAAP operating income for the quarter ending Dec. 31 was $17.6 million, compared to non-GAAP operating income of $22.9 million for the same period in 2010. Amylin reported cash, equivalents, short-term investments and restricted cash of $214.6 million as of Dec. 31. The company cited among 2011 operating highlights the FDA approval of Bydureon (exenatide extended-release for injectable suspension) as the first once-weekly medication approved in the U.S. and the European Union for Type II diabetes and the FDA approval of a new use for Byetta as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione. Shares of Amylin (NASDAQ:AMLN) gained 20 cents to close Tuesday at $16.89. (See BioWorld Today, Jan. 30, 2012.)